Validation of fluorouracil metabolite analysis in excised tumor - Lability of anabolites

被引:5
作者
Bading, JR
Shahinian, AH
Paff, MT
Yoo, PB
Hsia, DW
机构
[1] Univ So Calif, Dept Radiol, Los Angeles, CA USA
[2] Glaxo Wellcome Inc, Div Bioanal & Drug Metab, Res Triangle Pk, NC 27709 USA
关键词
antimetabolites; pyrimidines; fluorouracil; adenocarcinoma; metabolism; biological assay;
D O I
10.1016/S0006-2952(00)00421-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rapid excision and freezing of tissue commonly is assumed to preserve the molecular composition of the tissue just prior to its removal from the host. We examined the lability of radiolabeled 5-fluorouracil (FUra) and its anabolites during excision and freeze-clamping in a rat tumor model. Acid-soluble metabolites were identified by HPLC. Two rats, each bearing multiple, subcutaneously-implanted colon tumors, were treated with eniluracil (an inactivator of dihydropyrimidine dehydrogenase) to prevent catabolism of FUra and then injected intravenously with [H-3]FUra. After 2 hr, tumors were harvested sequentially and segmented. The tumor pieces were kept at room temperature for various times up to 4 min prior to freezing. These specimens showed a decrease (P < 0.01) in labeled nucleoside triphosphate content of 13 +/- 2%/min and commensurate increases (P < 0.005) in labeled nucleoside monophosphates and nucleosides with increasing time-to-freeze. The amounts of labeled macromolecules, nucleoside diphosphates, and FUra each remained approximately constant. The study indicates that substantial errors may occur in measured tissue concentrations of pyrimidine nucleosides and nucleotides due to lability during tissue excision and freeze-clamping. Such errors can be corrected using data of the type obtained in this study. BIOCHEM PHARMACOL 60;7:963-967, 2000. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:963 / 967
页数:5
相关论文
共 17 条
[1]  
Adams ER, 1999, CANCER RES, V59, P122
[2]  
Bading J. R., 1997, Journal of Nuclear Medicine, V38, p176P
[3]   SEQUENTIAL METHOTREXATE 5-FU - FDUMP FORMATION AND TS INHIBITION IN A TRANSPLANTABLE RODENT COLON ADENOCARCINOMA [J].
BERNE, MHO ;
GUSTAVSSON, BG ;
ALMERSJO, O ;
SPEARS, PC ;
FROSING, R .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 16 (03) :237-242
[4]   Role of fluoropyrimidine schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma [J].
Cao, SS ;
Frank, C ;
Rustum, YM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (07) :430-436
[5]  
Cao SS, 1995, CLIN CANCER RES, V1, P839
[6]  
CAO SS, 1994, CANCER RES, V54, P1507
[7]  
ELTAHTAWY A, 1991, CANCER RES, V51, P5806
[8]  
Fischel JL, 1995, CLIN CANCER RES, V1, P991
[9]  
HOUGHTON JA, 1980, CANCER, V45, P1159, DOI 10.1002/1097-0142(19800315)45:5+<1159::AID-CNCR2820451320>3.0.CO
[10]  
2-Z